Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H11: PET-Adapted Therapy for Advanced Hodgkin Lymphoma
NCT01652261Phase 3Withdrawn
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- May 2013
- Primary completion
- Oct 2014
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of doxorubicin, bleomycin, vinblastine, dacarbazine in Hodgkin lymphoma (HL), sponsored by European Organisation for Research and Treatment of Cancer. Planned start May 2013; status: withdrawn.
02
Drugs
doxorubicinbleomycinvinblastinedacarbazine
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT01652261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01652261.